Helen Macpherson, Pearce IP’s Executive Lawyer and Head of Litigation (Australia), has been recognised in 2027 The Best Lawyers in Australia™ for Intellectual Property Law and Life Sciences. Helen has been listed by Best Lawyers every year since 2017.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the fortnight ending 10 April 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 27 March 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 20 March 2026 are set out below…
IP Australia Proposes Changes to “Streamline and Simplify” Australia’s IP System. Earlier this month IP Australia issued a consultation paper seeking submissions on proposed reforms primarily to Australia’s current IP system. The consultation paper has been developed in conjunction with New Zealand Ministry of Business…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 March 2026 are set out below…
The One That Got Away – Aussie Fashion Designer Wins Trade Mark Stoush Against Katy Perry. The battle of the KATY(IE) PERRY trade marks has been ongoing since 2019, but thankfully the High Court of Australia has now settled the issue once and for all. In a decision handed down yesterday (11 March 2026)…
BREAKING NEWS: The High Court of Australia today granted special leave to Otsuka to appeal the decision of the Full Federal Court in Otsuka v Sun Pharma [2025] FCAFC 161 in which it unanimously held that pharmaceutical formulation patents are ineligible for patent term extension (PTE) in Australia.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 6 March 2026 are set out below…
FORXIGA® Injunction Breaks New Ground. As we have previously reported, Justice Downes of the Federal Court of Australia has set a new record for expedition in the patent dispute between AstraZeneca and Pharmacor, relating to the latter’s generic dapagliflozin.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 27 February 2026 are set out below…
HOT TOPIC | A Seismic Shift in Australian Pharma Patent Strategy | Fault Lines Emerge in PTEs and Preliminary Injunctions. Recent developments in Australian law and practice concerning Patent Term Extensions (PTEs) and preliminary injunctions (PIs) will shake up the pharmaceutical market. For originators, generics and biosimilar sponsors alike…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 20 February 2026 are set out below…
In this 60 minute Masterclass, a panel of expert senior Pearce IP lawyers and patent attorneys discuss changes and A Seismic Shift in Pharma Patent Law & Practice in Australia. Do Recent Developments in PTEs & PIs Create New Strategic Opportunities to Disrupt the Pharma Market?
Out With The In-Crowd – Gene Therapy For A Previously Excluded, Antibody-Positive Patient Group Ruled Non-Inventive. The Australian Patent Office has refused to grant a patent on Australian Patent Application 2018299865 in the name of uniQure IP B.V.
Lack of clarity sends patent claims down the drain – All Valve Industries Pty Ltd & Anor V Comino & Anor. In this article, we report on a Federal Court judgment in which Justice Halley determined two proceedings with a number of claims and cross-claims invoking statute, common law and equity.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 February 2026 are set out below…
WTR1000 2026 | Pearce IP “Shaking the Trans-Tasman Market”. Pearce IP, and 5 of its Executives, in Australia and New Zealand have been ranked in WTR 1000 2026 for trade marks: Litigation and Prosecution & Strategy. WTR 1000 was glowing in its commentary of Pearce IP…
In addition to recent rankings in the Chambers 2026 Asia-Pacific Guide, Pearce IP, with CEO Naomi Pearce and Executive & Head of Litigation Helen Macpherson, have been ranked overnight in the 2026 Chambers Global Guide. Whilst Chambers Asia-Pacific honours the best law firms and lawyers within the Asia-Pacific regional legal market, Chambers Global focuses on law firms and lawyers…
Australian Federal Court Moves Fast in Forxiga® Injunction Case. Justice Downes of the Federal Court of Australia is setting new records for timeliness in a pharmaceutical patent case. Following the hearing last Friday (6 February 2026), just over 7 weeks from AstraZeneca’s application for interlocutory injunction…
Pearce IP is pleased to announce the appointment of two new executives strengthening the firm’s leadership capabilities and depth of expertise. Mathew Lucas PhD joins the Melbourne team as Executive Patent & Trade Mark Attorney. James Tocci joins as Executive, Corporate Services.
This decision highlights the difference between disclosure under patent law and disclosure of confidential information and confirms that, just because an invention has been made “publicly available”, this does not mean that the invention has lost its confidential nature.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 6 February 2026 are set out below…
Seqirus has successfully opposed Moderna’s: AU2015249553 patent application (AU553) for nucleic acid vaccines; and AU2017326423 (AU423) for high purity RNA compositions and methods for preparation of these compositions.
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
